FEops elects Tom Fleming to its board of directors

Cardiovascular device veteran says FEops’ predictive R&D and procedure-planning platform, FEops HEARTguide™, is “pivotal” to facilitating enduring success for transcatheter-based device therapies

GENT, Belgium, Feb. 12, 2018 — FEops, a leader in personalized computational modeling and simulation for structural heart interventions, today announced that it has elected Tom Fleming to its board of directors, effective immediately. In his most recent role, Fleming served for over five years as Vice President and General Manager for Boston Scientific Corporation in the Structural Heart Valve business. He has been active in the cardiovascular device market for more than two decades.

“The addition of an industry veteran with the stature of Tom Fleming to our board further substantiates the extraordinary opportunity for FEops to become a primary catalyst in the way novel transcatheter-based structural heart solutions are being developed and interventional cardiovascular procedures are preoperatively planned,” said Dr. Matthieu De Beule, FEops CEO and Founder.

“FEops has identified a rapidly expanding patient population undergoing transcatheter device procedures who would benefit considerably from its patient-focused procedure-planning approach,” added Rob Michiels, Chairman of FEops, “and the inclusion of Tom Fleming to our team is a tremendous endorsement of the FEops technology platform. Given his hands-on operational and business-development achievements in the percutaneous valve replacement sectors, along with his extensive experience in the cardiovascular device industry overall, Tom will be of great value to FEops’ evolving strategic direction.”

“The future of Medical Device innovation will continue to evolve into treating more complex patients, and FEops computational modeling and simulation capabilities have the opportunity to lead in faster product development and clinical cycles with better patient outcomes” said Tom Fleming.

FEops HEARTguide™ proprietary array of products use advanced personalized computational modeling and simulation to provide clinicians and medical device manufacturers with first-ever insights into the interaction between transcatheter structural heart devices and specific patient anatomy – preoperatively. Such insights have the power to accelerate research and development of novel device-based solutions, as well as ultimately improve clinical outcomes in real-world hospital settings.

About FEops
Privately held FEops, headquartered in Gent, Belgium, is a leader in personalized computational modeling and simulation for structural heart interventions. In September 2017, FEops announced that it closed a 6 million euros financing, led by Valiance, and joined by existing investors Capricorn Venture Partners and PMV. Backed by strong preclinical data, FEops HEARTguide™ presents a prime opportunity to integrate transcatheter structural heart device design with patient-specific testing, and to do so virtually, cost-effectively and in a clinically meaningful way. Showcasing a pipeline of simulation products for structural heart, including TAVI (Transcatheter Aortic Valve Implantation), mitral and tricuspid valve replacement, and LAAO, FEops has the ambition to enable wider adoption of transcatheter approaches by minimizing the risk of life-threatening complications while reducing cost, and thus improve patient care. www.feops.com

-END-